ORIC Pharma - ORIC Quarterly EPS earnings growth

Corporate company logo of ORIC Pharmaceuticals, Inc. (ORIC)

High costs for early-stage oncology drug trials are creating financial pressure, as evidenced by the quarterly EPS gap on the GURU.Markets chart, where 17.20 reflects the latest metric value. The stability of ORIC Pharmaceuticals (ORIC) relies on regulatory approvals and investment inflows. Future revenue is based on the commercialization of agents designed to overcome drug resistance in cancer.

oricpharma.com (ORIC) Year-over-year earnings per one share growth for the last 12 months: for the period 07/04/2022 - 11/10/2026

Analytical breakdowns for ORIC Pharmaceuticals

- share price and consensus valuation forecast:
Stock Quotes ORIC Pharmaceuticals, Inc.|ORIC - Analyst Forecast Prices
- issuer market value details:
Market Capitalization ORIC Pharma|ORIC - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Single Share ORIC Pharmaceuticals|ORIC - Accounting Value of Company|Market Capitalization to Book Value Ratio oricpharma.com|ORIC - Company Balance Sheet Assets
- debt and liquidity data:
Total Debt to Capital ORIC Pharmaceuticals|ORIC - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio ORIC Pharmaceuticals|ORIC - Company Cumulative Indebtedness|Debts to Book Capitalization ORIC Pharma|ORIC - Long-Term Debt|Company Short-Term Debts ORIC Pharmaceuticals|Quick Liquidity Indicator oricpharma.com
- earnings and market multiples details:
ORIC - Final Profit|Future Profit ORIC Pharmaceuticals|ORIC - Market Price to Net Income Ratio|Forward P/E Multiple ORIC Pharma|ORIC - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ORIC Pharma|ORIC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months ORIC Pharmaceuticals|ORIC - Earnings per share for the trailing year|Quarterly EPS earnings growth oricpharma.com|ORIC - Earnings growth in current year|Net earnings per share growth forecast for next year ORIC Pharmaceuticals
Fundamental company valuation:ORIC Pharmaceuticals, Inc. - ORIC
Flagship merchandise of oricpharma.com

ORIC Pharmaceuticals is investing in R&D without commercial products, leading to a planned depletion of reserves. This metric measures the percentage change in earnings per share between quarters, reflecting the efficiency of capital management. The indicator allows for an assessment of reporting transparency and the cash burn rate. This analysis helps determine the risk of overpaying for future successes. The history of quarterly EPS growth visualizes these financial fluctuations.

Analysis of competing companies

GMAB (Genmab) - Year-over-year net earnings per share growth for the last 12 months|EXEL: Year-over-year earnings per share growth rate for the last twelve months|NUVL (Nuvalent Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth Kymera Corp|Year-over-year earnings per share growth for the last twelve months IDEAYA Biosciences (IDYA)|ELVN (enliventherapeutics.com) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth RLAY (Relay Therapeutics, Inc.)|Net earnings per share growth for the trailing year Nurix Therapeutics Inc|Tyra Bio - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Verastem Corp|GLUE (Monte Rosa Therapeutics) - Year-over-year net earnings per share growth for the last 12 months|CGEM: Year-over-year earnings per share growth rate for the last twelve months|IMRX (Immuneering) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months C4 Therapeutics Inc CCCC|Quarterly EPS earnings growth BDTX|Repare Therapeutics Inc - Year-over-year earnings per share growth for the last 12 months|PMV Pharmaceuticals - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months KPTI|PPCB: Year-over-year net earnings per share growth for the last 12 months|Bio Green Med Solution Inc. - Year-over-year earnings per share growth rate for the last twelve months|AADI: Quarterly EPS earnings growth|Aileron Therapeutics, Inc. - Year-over-year earnings per one share growth for the last 12 months|BPMC (Blueprint Medicines Corp.) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months GlycoMimetics Corp GLYC|Year-over-year earnings per share growth for the last twelve months SpringWorks Therapeutics, Inc. (SWTX)